Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
AssigneesThe Governors of the University of Alberta, Alberta Health Services
InventorsMichael WEINFELD, Dennis G. HALL, Feridoun KARIMI-BUSHERI, Gary Kenneth FRESCHAUF, Todd Randall MERENIUK
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
Claims21
A kit for increasing the sensitivity of a cancerous cell to a radiation therapy, said kit comprising:
- a polynucleotide kinase/phosphatase (PNKP) inhibitor or pharmaceutically acceptable salt thereof;
- and instructions for the use thereof.
A compound or pharmaceutically acceptable salt thereof for increasing the sensitivity of a cancerous cell of a patient to a radiation therapy, said compound comprising a polynucleotide kinase/phosphatase (PNKP) inhibitor.
A method of radio sensitizing a cancerous cell in a mammal in need of radiation therapy, comprising:
- administering to said mammal a polynucleotide kinase/phosphatase (PNKP) inhibitor or pharmaceutically acceptable salt thereof.
An improved method for radiation therapy of a patient with a cancer employing a radiation sensitizer, wherein the improvement comprises treating said patient with an effective amount of a polynucleotide kinase/phosphatase (PNKP) inhibitor or pharmaceutically acceptable salt thereof.
A method of inhibiting the phosphatase activity of polynucleotide kinase/phosphatase (PNKP), comprising:
- contacting a cell with a compound or pharmaceutically acceptable salt thereof selected from A12B4C3, A1B4C3, A6B4C3, A26B11C2 or A39B1C2.
Dependencies are inferred from the claim text.